Key result
Sirolimus-eluting stents linked to ~16% clinically driven TLR rate beyond 10 years.
Why the study?
Clinical outcomes after PCI have improved with drug-eluting stents, but data beyond 10 years are limited.
Cohort (n=885)
No
Events such as clinically driven target lesion revascularization continue to occur beyond 10 years after sirolimus-eluting stent implantation, with an increasing proportion triggered by acute coronary syndromes.
Very late revascularization events occur after sirolimus-eluting stents; leaves open whether contemporary platforms require similar extended surveillance.
BACKGROUND: Clinical outcomes after percutaneous coronary intervention have improved with the use of drug-eluting stents, but data beyond 10 years are limited. The purpose of this study was to evaluate the clinical outcomes of patients undergoing sirolimus-eluting stent implantation with follow-up beyond 10 years and to determine the impact of clinical and angiographic characteristics on long-term prognosis. METHODS AND RESULTS: The clinical outcomes of 885 patients who had undergone sirolimus-eluting stent implantation at a single institution were retrospectively reviewed. Primary endpoints included in the analysis were clinically driven target lesion revascularization (cTLR) and target lesion revascularization (TLR). Univariate and multivariate nominal logistic regression was used for data analysis. The incidence rates of cTLR and TLR beyond 10 years after sirolimus-eluting stent implantation were 16.4% and 36.8%, respectively, with cTLR tending to decrease beyond 10 years. Acute coronary syndrome was a predominant trigger for cTLR. Age, statin use, and stent restenosis emerged as predictors of cTLR within 10 years, but no significant predictors other than age were identified beyond 10 years. CONCLUSIONS: Events continue to occur beyond 10 years after sirolimus-eluting stent implantation, with a trend toward an increase in acute coronary syndromes. It is important to be vigilant about the occurrence of acute coronary syndromes during long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Nishiura et al. (2024) conducted a cohort in Percutaneous coronary intervention (n=885). Sirolimus-eluting stent implantation was evaluated on Clinically driven target lesion revascularization (cTLR) and target lesion revascularization (TLR). Sirolimus-eluting stent implantation was associated with long-term incidence rates of 16.4% for clinically driven target lesion revascularization and 36.8% for target lesion revascularization beyond 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: